Status:
NOT_YET_RECRUITING
Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda
Lead Sponsor:
Rwanda Biomedical Centre
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Karolinska Institutet
Conditions:
Cervical Cancer
Eligibility:
FEMALE
23-29 years
Phase:
PHASE4
Brief Summary
Cervical cancer is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women, with an estimated 604,000 new cases and 342,000 deaths worldwide in 2020. Rwanda i...
Eligibility Criteria
Inclusion
- Eligible women will include women within the age range of 23-29, who have not opted out of the screening program and who consent to participate in the study
Exclusion
- Known history of severe allergic reaction or hypersensitivity to any of the components of the HPV vaccine. (For GARDASIL 9: Amorphous aluminium hydroxyphosphate sulphate adjuvant, Sodium chloride, L-histidine, Polysorbate 80, or Sodium borate)
- Known history of immune-related disorders
- Current acute severe febrile illness, except for minor infections such as a cold, mild upper respiratory infection, or low-grade fever.
- Administration of immunoglobulin or blood-derived products within 6 months prior to the scheduled HPV vaccine first dose
- Current pregnancy (reported)
- Women with a total hysterectomy
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2026
Estimated Enrollment :
100000 Patients enrolled
Trial Details
Trial ID
NCT06536855
Start Date
September 1 2024
End Date
March 30 2026
Last Update
August 5 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.